EA200300048A1 - Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу - Google Patents

Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу

Info

Publication number
EA200300048A1
EA200300048A1 EA200300048A EA200300048A EA200300048A1 EA 200300048 A1 EA200300048 A1 EA 200300048A1 EA 200300048 A EA200300048 A EA 200300048A EA 200300048 A EA200300048 A EA 200300048A EA 200300048 A1 EA200300048 A1 EA 200300048A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharnesiltransferase
hinazoline
annelied
enantiomer
inhibiting
Prior art date
Application number
EA200300048A
Other languages
English (en)
Other versions
EA005065B1 (ru
Inventor
Марк Гастон Вене
Патрик Рене Анжибо
Дэвид Вилльям Энд
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200300048A1 publication Critical patent/EA200300048A1/ru
Publication of EA005065B1 publication Critical patent/EA005065B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к (-)-5-(3-хлорфенил)-α-(4-хлорфенил)-α-(1-метил-1Н-имидазол-5-ил)тетразоло[1,5-а]хиназолин-7-метанамину и его фармацевтически приемлемым кислотно-аддитивным солям, использованию данных соединений в медицине, главным образом, для лечения раковых заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300048A 2000-06-22 2001-06-13 Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу EA005065B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number Publication Date
EA200300048A1 true EA200300048A1 (ru) 2003-04-24
EA005065B1 EA005065B1 (ru) 2004-10-28

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300048A EA005065B1 (ru) 2000-06-22 2001-06-13 Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу

Country Status (34)

Country Link
US (3) US20030114471A1 (ru)
EP (1) EP1296984B1 (ru)
JP (1) JP4919575B2 (ru)
KR (2) KR100846370B1 (ru)
CN (1) CN1207296C (ru)
AR (1) AR030704A1 (ru)
AT (1) ATE294804T1 (ru)
AU (3) AU6396201A (ru)
BG (1) BG65894B1 (ru)
BR (1) BRPI0111743B8 (ru)
CA (1) CA2410232C (ru)
CZ (1) CZ295278B6 (ru)
DE (1) DE60110592T2 (ru)
EA (1) EA005065B1 (ru)
EE (1) EE04966B1 (ru)
EG (1) EG24180A (ru)
ES (1) ES2241830T3 (ru)
HK (1) HK1058363A1 (ru)
HR (1) HRP20020989B1 (ru)
HU (1) HU229095B1 (ru)
IL (2) IL153560A0 (ru)
IS (1) IS2596B (ru)
JO (1) JO2361B1 (ru)
MX (1) MXPA02012845A (ru)
MY (1) MY127734A (ru)
NO (1) NO324494B1 (ru)
NZ (1) NZ522481A (ru)
PA (1) PA8519501A1 (ru)
PL (1) PL209521B1 (ru)
SA (1) SA01220349B1 (ru)
SK (1) SK285699B6 (ru)
UA (1) UA73572C2 (ru)
WO (1) WO2001098302A1 (ru)
ZA (1) ZA200210305B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
HUE049620T2 (hu) 2015-08-17 2020-09-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
ES2863730T3 (es) 2016-11-03 2021-10-11 Kura Oncology Inc Inhibidores de la farnesiltransferasa para uso en el tratamiento del cáncer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CA2231105C (en) * 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
PT988038E (pt) 1997-06-02 2002-12-31 Janssen Pharmaceutica Nv Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
DK1094839T3 (da) * 1998-07-06 2003-08-18 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
EE04579B1 (et) 1998-07-06 2006-02-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
AU4925499A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
BR9913315A (pt) * 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
CN1340051A (zh) * 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2397558A1 (en) * 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
JP4974438B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体

Also Published As

Publication number Publication date
KR100831940B1 (ko) 2008-05-23
CN1207296C (zh) 2005-06-22
CZ2003114A3 (cs) 2003-05-14
IS2596B (is) 2010-03-15
EP1296984A1 (en) 2003-04-02
AU2006220405A1 (en) 2006-10-12
DE60110592T2 (de) 2006-01-19
NO324494B1 (no) 2007-10-29
IL153560A (en) 2011-06-30
EE04966B1 (et) 2008-02-15
PL209521B1 (pl) 2011-09-30
JP2004501153A (ja) 2004-01-15
SK285699B6 (sk) 2007-06-07
SA01220349B1 (ar) 2007-01-23
HUP0300872A2 (hu) 2003-07-28
NO20026032L (no) 2002-12-16
EA005065B1 (ru) 2004-10-28
ZA200210305B (en) 2004-03-19
MXPA02012845A (es) 2003-05-15
US8329714B2 (en) 2012-12-11
HK1058363A1 (en) 2004-05-14
DE60110592D1 (de) 2005-06-09
SK502003A3 (en) 2003-05-02
ES2241830T3 (es) 2005-11-01
IS6590A (is) 2002-10-25
ATE294804T1 (de) 2005-05-15
EP1296984B1 (en) 2005-05-04
EE200200695A (et) 2004-06-15
UA73572C2 (en) 2005-08-15
WO2001098302A1 (en) 2001-12-27
NO20026032D0 (no) 2002-12-16
US20080114009A1 (en) 2008-05-15
NZ522481A (en) 2004-09-24
PL358918A1 (en) 2004-08-23
BRPI0111743B1 (pt) 2019-03-26
KR20070121847A (ko) 2007-12-27
CA2410232C (en) 2008-10-07
KR20030009463A (ko) 2003-01-29
AR030704A1 (es) 2003-09-03
HU229095B1 (en) 2013-07-29
CA2410232A1 (en) 2001-12-27
BG107310A (bg) 2003-07-31
CZ295278B6 (cs) 2005-06-15
US8318753B2 (en) 2012-11-27
EG24180A (en) 2008-09-28
US20070259902A1 (en) 2007-11-08
JP4919575B2 (ja) 2012-04-18
JO2361B1 (en) 2006-12-12
BRPI0111743B8 (pt) 2021-05-25
KR100846370B1 (ko) 2008-07-15
CN1437601A (zh) 2003-08-20
HRP20020989A2 (en) 2005-02-28
IL153560A0 (en) 2003-07-06
AU2006220405B2 (en) 2009-05-21
HRP20020989B1 (en) 2011-05-31
AU6396201A (en) 2002-01-02
US20030114471A1 (en) 2003-06-19
MY127734A (en) 2006-12-29
BG65894B1 (bg) 2010-04-30
PA8519501A1 (es) 2002-08-29
BR0111743A (pt) 2003-07-08
AU2001263962B2 (en) 2006-07-20
HUP0300872A3 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
MY133667A (en) Quinazoline ditosylate salt compounds
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200100764A1 (ru) Трициклические ингибиторы поли(adp-рибозо) полимераз
WO2001039763A3 (en) Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
EA200001043A2 (ru) Соединения для лечения женской сексуальной дисфункции
EA200200862A1 (ru) Пирролзамещенный 2-индолинон и промежуточный пиррол, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
RS51123B (sr) Aril fuzionisana azapoliciklična jedinjenja
GB0112348D0 (en) Compounds
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
MY129635A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
EP0725641A4 (ru)
EA200300048A1 (ru) Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу
DE60106409D1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
SE9902267D0 (sv) New compounds
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
WO2001007029A3 (en) Substituted guanidines and the use thereof
ATE296631T1 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
EA200300725A1 (ru) Соединение азола в качестве противогрибковых средств

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MK4A Patent expired

Designated state(s): KZ RU